Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement

RET rearrangements are rare, and occur in 1%-2% of all non-small cell lung cancer (NSCLC) patients. Pralsetinib has a significant anti-tumor effect in patients with advanced NSCLC and a RET rearrangement. Previous studies have confirmed the efficiency of neoadjuvant target therapy for NSCLC. Herein...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ning, Li, Tong, Liang, Maoli, Ren, Fan, Ni, Hong, Liu, Wei, Shi, Tao, Xu, Dongbo, Chen, Qiusong, Yu, Haonan, Song, Zuoqing, Zu, Lingling, Li, Shuo, Xu, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866561/
https://www.ncbi.nlm.nih.gov/pubmed/35223529
http://dx.doi.org/10.3389/fonc.2022.848779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866561/
https://www.ncbi.nlm.nih.gov/pubmed/35223529
http://dx.doi.org/10.3389/fonc.2022.848779

Ejemplares similares